BofA raised the firm’s price target on Alnylam to $295 from $248 and keeps a Buy rating on the shares after the HELIOS-B trial of vutrisiran in ATTR-cardiomyopathy, or ATTR-CM, met the composite primary endpoint in the overall and the monotherapy arms and all key secondary endpoints were also met in both groups. The firm, which says it is “highly encouraged by the large commercial opportunity in ATTR-CM based on these results,” now models $7.9B in risk-adjusted peak sales in ATTR-CM.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam (NASDAQ:ALNY) Soars on Positive Topline Results for Vutrisiran
- Alnylam reports results from its HELIOS-B Phase 3 study of vutrisiran
- Ionis Pharmaceuticals upgraded to Market Perform from Underperform at Bernstein
- Citi opens ‘positive catalyst watch’ on Alnylam in data readout
- Alnylam price target raised to $400 from $395 at H.C. Wainwright